Bronstein, Gewirtz and Grossman, LLC announces that shareholders of Inari Medical, Inc. have the opportunity to file a class action lawsuit!

NEW YORK CITY, NY / ACCESSWIRE / July 7, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Inari Medical, Inc. (“Inari” or “the Company”) (NASDAQ:NARI) and certain of its officers.

Class definition:

This action seeks to recover damages from Defendants for alleged violations of the federal securities laws on behalf of all persons and entities who purchased or otherwise acquired Inari securities between March 10, 2021 and February 28, 2024, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the Company’s website: bgandg.com/NARI.

Case details:

The complaint alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

Inari is a medical device company that develops and manufactures a variety of products, including minimally invasive, novel, catheter-based mechanical thrombectomy devices and their accessories to address the unique characteristics of specific disease states. These products are designed to improve treatment outcomes for patients with venous thromboembolism (“VTE”) and other vascular diseases and conditions. Throughout the Class Period, defendants consistently touted Inari’s “record sales,” which they claimed were driven by “the strength of our core VTE business.” However, the complaint alleges that defendants failed to disclose that a significant portion of their expenditures were used to improperly compensate healthcare professionals for the use of Inari products. The complaint further alleges that while defendants spoke positively about the company’s growth prospects, the company engaged in illegal business practices and improperly compensated healthcare professionals in violation of the federal Anti-Kickback Act and the Civil False Statements Act. Finally, the lawsuit alleges that the defendants also misled investors about business expenses in order to conceal their unlawful conduct.

What’s next?

A class action lawsuit has already been filed. If you would like to review a copy of the lawsuit, you can visit the firm’s website: bgandg.com/NARI or you can contact Peretz Bronstein, Esq. or his Client Relations Manager Nathan Miller of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660. If you suffered a loss in Inari, you have until July 12, 2024 to request that the court appoint you as lead plaintiff. Your ability to share in any compensation is not dependent on your serving as lead plaintiff.

There are no costs for you

We represent investors in class action lawsuits on a contingency basis, meaning we ask the court to reimburse us for our expenses and attorney fees (usually a percentage of the total award) only if we win.

Why Bronstein, Gewirtz & Grossman:

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized law firm representing investors in securities fraud class action lawsuits and shareholder actions involving derivatives trading. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Attorney advertising. Past results do not guarantee similar results.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller,
332-239-2660 | (email protected)

SOURCE: Bronstein, Gewirtz & Grossman, LLC